Clinical Trial

Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to test GT-220F in patients with metastatic castration resistant prostate cancer and learn about the best dose required for further study. Participants will be adults with metastatic castration resistant prostate cancer. The main questions the study aims to answer are: 1) What medical problems do participants have when taking GT-220F? 2) What dose strength is best to use in further clinical trials? Participants will be asked to * take GT-220F every day * take medical tests every week
Trial Details
NCT Number NCT06866795
Lead Sponsor Geode Therapeutics Inc.
Conditions Metastatic Castration Resistant Prostate Cancer
Enrollment 42 participants
Start Date 2025-07
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-10